COMPUGEN LTD
CGEN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CGEN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CGEN
Compugen Ltd. is a clinical-stage immuno-oncology company leveraging its proprietary Unigen platform to discover and develop novel therapeutic antibodies, with partnered programs in Phase 3 and Phase 1 trials and a recent shift to profitability in 2025.
Key risk: No regulatory approval history
BioSniper Score
Based on 4 of 6 signals
Financial data as of Dec 31, 2025.
Tracking 3 clinical trials · 3 catalysts for COMPUGEN LTD.
Compugen Ltd. is a clinical-stage immuno-oncology company leveraging its proprietary Unigen platform to discover and develop novel therapeutic antibodies, with partnered programs in Phase 3 and Phase 1 trials and a recent shift to profitability in 2025.
- Reported net profit of $35.3 million in 2025, compared to net losses of $14.2 million in 2024 and $18.8 million in 2023 [sec · filed 2026-03-02].
- Cash and equivalents of $90.6 million as of 2025-12-31 [sec].
- Two active collaborations: AstraZeneca developing rilvegostomig (anti PD-1/TIGIT bispecific) in multiple Phase 3, Phase 2 and Phase 1 trials, and Gilead developing GS-0321 (formerly COM503) in Phase 1 [sec · filed 2026-03-02].
- Internal pipeline includes COM701, currently in Phase 2 clinical development [sec · filed 2026-03-02].
- Accumulated deficit of $488.8 million as of December 31, 2024 [sec · filed 2025-03-04].
What works
- Achieved net profitability of $35.3 million in 2025, a significant turnaround from prior-year losses [sec · filed 2026-03-02].
- Two major pharmaceutical partnerships (AstraZeneca and Gilead) validate the Unigen platform and provide potential milestone and royalty revenue streams [sec · filed 2025-03-04].
- Rilvegostomig, partnered with AstraZeneca, has advanced into multiple Phase 3 trials, indicating progress toward potential commercialization [sec · filed 2025-03-04].
- The Unigen platform has generated four product candidates currently in clinical evaluation, demonstrating ongoing discovery capability [sec · filed 2025-03-04].
What to weigh
- Accumulated deficit of $488.8 million as of December 31, 2024, reflecting years of net losses and high R&D spending [sec · filed 2025-03-04].
- The company has never progressed a product candidate through to regulatory approval and has limited experience conducting clinical trials [sec · filed 2026-03-02].
- Business model depends on future collaboration revenues (milestones, royalties) which are uncertain; only two of four collaboration agreements remain in effect [sec · filed 2026-03-02].
- Clinical development is expensive and uncertain; early trial results may not predict later success, and delays or failures could harm the business [sec · filed 2026-03-02].
From the filings
Quoted directly from source documents.
Compugen achieved net profit in 2025 after years of losses.
“We incurred net profit of approximately $35.3 million in 2025, and net loss of approximately $14.2 million in 2024 and approximately $18.8 million in 2023.”
SEC filings · March 2, 2026
The company has a large accumulated deficit.
“as of December 31, 2024, we had an accumulated deficit of $488.8 million.”
SEC filings · March 4, 2025
Compugen has two active partnerships with AstraZeneca and Gilead.
“We have two partnerships in place, one with AstraZeneca, who is developing rilvegostomig, an anti PD-1/TIGIT bispecific antibody with a TIGIT-specific component that is derived from our COM902 antibody and is in multiple Phase 3, Phase 2 and Phase 1 clinical trials, and the second, with Gilead, pursuant to a license agreement for our GS-0321 (previously COM503) program, which is currently in Phase 1 clinical trial.”
SEC filings · March 2, 2026
The company has never obtained regulatory approval for any product.
“As a company, we have limited experience in conducting clinical trials and have never progressed a product candidate through to regulatory approval.”
SEC filings · March 2, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline · com701 — Phase 2 Readout: com701 — Top-line data from the Phase 2 trial of COM701 will be a key readout for the internal pipeline.
- 2027-03-31 · Phase2_Topline · com701 — Phase 2 Readout: com701 — Additional Phase 2 top-line data for COM701 expected in early 2027.
- 2027-03-31 · Phase2_Topline · maia — Phase 2 Readout: maia — Phase 2 top-line data for the maia program are anticipated by March 2027.
Risks & what to watch (4)›
Key risks
- No regulatory approval history — Compugen has never progressed a product candidate through to regulatory approval, increasing execution risk [sec · filed 2026-03-02].
- Dependence on partnerships — Business model relies on collaboration revenues; only two of four agreements remain active [sec · filed 2026-03-02].
- Clinical trial uncertainty — Early clinical results may not predict later success; trials may be delayed or fail [sec · filed 2026-03-02].
- History of losses — Accumulated deficit of $488.8M as of Dec 2024; future losses may continue [sec · filed 2025-03-04].
What to watch
- Phase 2 top-line data for COM701 expected by end of 2026 or early 2027 [catalyst_timeline].
- Phase 2 top-line data for maia program expected by March 2027 [catalyst_timeline].
- Progress of Gilead-partnered GS-0321 (COM503) through Phase 1 development [sec · filed 2026-03-02].
- AstraZeneca's advancement of rilvegostomig in Phase 3 trials and any regulatory milestones [sec · filed 2025-03-04].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run COMPUGEN LTD through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available COMPUGEN LTD facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Profitable (positive operating cash flow)
D/E 0.52 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
3 upcoming, next in ~123d
0 buys · 11 sells (180d)
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
75
Total value held
$28.5M
| Holder | Shares | Value |
|---|---|---|
| silverarc capital management, llc | 3,315,845 | $7.1M |
| renaissance technologies llc | 1,632,988 | $3.5M |
| morgan stanley | 1,053,229 | $2.2M |
| ark investment management llc | 1,049,873 | $2.2M |
| nomura asset management international inc. | 1,020,000 | $2.2M |
| northern trust corp | 650,868 | $1.4M |
| two sigma investments, lp | 521,587 | $1.1M |
| state street corp | 415,366 | $885K |
| ubs group ag | 306,708 | $653K |
| wells fargo & company/mn | 3,100 | $646K |
Showing top 10 of 75 institutional holders of COMPUGEN LTD. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 1.5%
- Days to cover
- 2.7
- Shares short
- 1,422,380
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CGEN short interestFrequently asked questions
What is the AI investment thesis for COMPUGEN LTD?
Compugen Ltd. is a clinical-stage immuno-oncology company leveraging its proprietary Unigen platform to discover and develop novel therapeutic antibodies, with partnered programs in Phase 3 and Phase 1 trials and a recent shift to profitability in 2025.
What is COMPUGEN LTD's next catalyst?
COMPUGEN LTD's next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: com701" — expected December 31, 2026.
Who is the CEO of COMPUGEN LTD?
Dr. Eran Ophir Ph.D. is the chief executive officer of COMPUGEN LTD (CGEN).
Where is COMPUGEN LTD headquartered?
COMPUGEN LTD (CGEN) is headquartered in Holon, Israel.
What therapeutic areas does COMPUGEN LTD focus on?
COMPUGEN LTD develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.